J INTS BIO, Oral TKI 'JIN-A04', poster presentation of HER2 exon20 insertion mutation in NSCLC

/PRNewswire/ -- J INTS BIO announced that the preclinical results of "JIN-A04," a novel oral tyrosine kinase inhibitor (TKI) targeting HER2 Exon20 insertion...

Related Keywords

United States ,Seoul ,Soult Ukpyolsi ,South Korea ,American , ,American Cancer Research Association ,Cancer Research Association ,J Ints Bio ,